Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

astrazeneca_building_white

AstraZeneca allowed to recruit for drug trial again

November 22, 2016
Manufacturing and Production, Research and Development AstraZeneca, FDA, clinical trial

AstraZeneca’s clinical trial for head and neck cancer had previously been put on partial hold by the FDA due to …

News
astrazeneca_building_white

AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …

News
astrazeneca_logo_building

AstraZeneca’s head and neck cancer treatment clinical trials put on hold

October 31, 2016
Sales and Marketing AstraZeneca, clinical hold, clinical trials, immunotherapy, phase III

AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …

News
cq5dam

AZ reveals compelling PhIII data for ovarian cancer treatment

October 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AZ, AstraZeneca, lynparza

AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy …

News
ema_inside

EMA opens clinical trial data to public

October 25, 2016
Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials

The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …

News
clinical_trial-web

Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

News
astrazeneca_logo_building

AstraZeneca forced to abandon Phase II trial

October 12, 2016
Research and Development AstraZeneca, Synairgen, asthma, cold, common cold

Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …

News

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News
astrazeneca_plaque

AZ “disappointment” at heart drug failure

October 5, 2016
Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …

News
astrazeneca_sign_sky

AstraZeneca’s wins major drug approval by NICE

October 4, 2016
Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso

AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …

News
medimmune

AstraZeneca agrees $250 million licensing agreement with Allergan

October 3, 2016
Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease

Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …

News
mark_zuckerberg_-_south_by_southwest_2008

Zuckerberg appoints AstraZeneca’s Cornelia Bargmann

September 28, 2016
Research and Development AstraZeneca, Facebook, Mark Zuckerberg, Priscilla Chan

Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …

News

AZ withdraws European filing for ovarian cancer therapy

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer

AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …

News
microsoft-80658_1280

AstraZeneca and Microsoft to develop ‘drag and drop’ cancer simulation

September 21, 2016
Medical Communications, Research and Development AstraZeneca, Digital Pharma Guide, Microsoft

AstraZeneca has entered into a partnership with tech giant Microsoft to develop a new computerised modelling system which promises to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025